Dimethyl fumarate for treating relapsing multiple sclerosis

William Sheremata, Andrew D. Brown, Kottil W Rammohan

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Introduction: Outcomes of two large double-blind placebo-controlled studies of oral dimethyl fumarate (DMF) in multiple sclerosis (MS) provided the basis for its marketing approval as Tecfidera® by the US FDA in early 2013 and the European Medicines Agency in February 2014. The safety of DMF is complemented by experience in the use of an oral mixture of fumaric acid esters, including DMF for psoriasis (Fumaderm®; DMF and monoethyl fumarate [DMF-MEF]) licensed in Germany in 1994.Areas covered: This article reviews the pivotal trials leading to the approval of DMF for MS and the pharmacological literature related to the extensive use of oral fumaric acid esters for psoriasis over the last quarter century. Anecdotal reports of serious adverse reactions to DMF-MEF are also reviewed in this report.Expert opinion: DMF is generally safe and well tolerated. Flushing and gastrointestinal side effects are relatively common for the approved DMF dose but are ordinarily mild and self-limited. No increase in malignancies has been reported despite theoretical concerns. Although progressive multifocal encephalopathy has been reported anecdotally in 5 of > 196,000 patient-years of experience with fumaric acid esters, none of the 65,000 DMF MS patients treated in the first year has been affected.Appendix to the abstract: Subsequent to the acceptance of this article for publication, the manufacturer has notified physicians of the death of one patient from PML complicating use of DMF in the DEFINE study extension (ENDORSE). This does not alter the expert opinion rendered regarding the safety of DMF. We await the outcomes and recommendations from the ongoing investigation into this case.

Original languageEnglish
Pages (from-to)161-170
Number of pages10
JournalExpert Opinion on Drug Safety
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Multiple Sclerosis
Fumarates
Expert Testimony
Psoriasis
Dimethyl Fumarate
Safety
Brain Diseases
Marketing
Germany
Publications
Placebos
Pharmacology
Physicians

Keywords

  • Dimethyl fumarate
  • Fumarate
  • Lymphopenia
  • Monoethyl fumarate
  • Multiple sclerosis
  • Neuroprotection
  • Nuclear factor (erythroid-derived-2)-like 2
  • Progressive multifocal encephalopathy

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Dimethyl fumarate for treating relapsing multiple sclerosis. / Sheremata, William; Brown, Andrew D.; Rammohan, Kottil W.

In: Expert Opinion on Drug Safety, Vol. 14, No. 1, 01.01.2015, p. 161-170.

Research output: Contribution to journalArticle

Sheremata, William ; Brown, Andrew D. ; Rammohan, Kottil W. / Dimethyl fumarate for treating relapsing multiple sclerosis. In: Expert Opinion on Drug Safety. 2015 ; Vol. 14, No. 1. pp. 161-170.
@article{1adf9e7318014b2f86dde4c8f811159f,
title = "Dimethyl fumarate for treating relapsing multiple sclerosis",
abstract = "Introduction: Outcomes of two large double-blind placebo-controlled studies of oral dimethyl fumarate (DMF) in multiple sclerosis (MS) provided the basis for its marketing approval as Tecfidera{\circledR} by the US FDA in early 2013 and the European Medicines Agency in February 2014. The safety of DMF is complemented by experience in the use of an oral mixture of fumaric acid esters, including DMF for psoriasis (Fumaderm{\circledR}; DMF and monoethyl fumarate [DMF-MEF]) licensed in Germany in 1994.Areas covered: This article reviews the pivotal trials leading to the approval of DMF for MS and the pharmacological literature related to the extensive use of oral fumaric acid esters for psoriasis over the last quarter century. Anecdotal reports of serious adverse reactions to DMF-MEF are also reviewed in this report.Expert opinion: DMF is generally safe and well tolerated. Flushing and gastrointestinal side effects are relatively common for the approved DMF dose but are ordinarily mild and self-limited. No increase in malignancies has been reported despite theoretical concerns. Although progressive multifocal encephalopathy has been reported anecdotally in 5 of > 196,000 patient-years of experience with fumaric acid esters, none of the 65,000 DMF MS patients treated in the first year has been affected.Appendix to the abstract: Subsequent to the acceptance of this article for publication, the manufacturer has notified physicians of the death of one patient from PML complicating use of DMF in the DEFINE study extension (ENDORSE). This does not alter the expert opinion rendered regarding the safety of DMF. We await the outcomes and recommendations from the ongoing investigation into this case.",
keywords = "Dimethyl fumarate, Fumarate, Lymphopenia, Monoethyl fumarate, Multiple sclerosis, Neuroprotection, Nuclear factor (erythroid-derived-2)-like 2, Progressive multifocal encephalopathy",
author = "William Sheremata and Brown, {Andrew D.} and Rammohan, {Kottil W}",
year = "2015",
month = "1",
day = "1",
doi = "10.1517/14740338.2015.977251",
language = "English",
volume = "14",
pages = "161--170",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Dimethyl fumarate for treating relapsing multiple sclerosis

AU - Sheremata, William

AU - Brown, Andrew D.

AU - Rammohan, Kottil W

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: Outcomes of two large double-blind placebo-controlled studies of oral dimethyl fumarate (DMF) in multiple sclerosis (MS) provided the basis for its marketing approval as Tecfidera® by the US FDA in early 2013 and the European Medicines Agency in February 2014. The safety of DMF is complemented by experience in the use of an oral mixture of fumaric acid esters, including DMF for psoriasis (Fumaderm®; DMF and monoethyl fumarate [DMF-MEF]) licensed in Germany in 1994.Areas covered: This article reviews the pivotal trials leading to the approval of DMF for MS and the pharmacological literature related to the extensive use of oral fumaric acid esters for psoriasis over the last quarter century. Anecdotal reports of serious adverse reactions to DMF-MEF are also reviewed in this report.Expert opinion: DMF is generally safe and well tolerated. Flushing and gastrointestinal side effects are relatively common for the approved DMF dose but are ordinarily mild and self-limited. No increase in malignancies has been reported despite theoretical concerns. Although progressive multifocal encephalopathy has been reported anecdotally in 5 of > 196,000 patient-years of experience with fumaric acid esters, none of the 65,000 DMF MS patients treated in the first year has been affected.Appendix to the abstract: Subsequent to the acceptance of this article for publication, the manufacturer has notified physicians of the death of one patient from PML complicating use of DMF in the DEFINE study extension (ENDORSE). This does not alter the expert opinion rendered regarding the safety of DMF. We await the outcomes and recommendations from the ongoing investigation into this case.

AB - Introduction: Outcomes of two large double-blind placebo-controlled studies of oral dimethyl fumarate (DMF) in multiple sclerosis (MS) provided the basis for its marketing approval as Tecfidera® by the US FDA in early 2013 and the European Medicines Agency in February 2014. The safety of DMF is complemented by experience in the use of an oral mixture of fumaric acid esters, including DMF for psoriasis (Fumaderm®; DMF and monoethyl fumarate [DMF-MEF]) licensed in Germany in 1994.Areas covered: This article reviews the pivotal trials leading to the approval of DMF for MS and the pharmacological literature related to the extensive use of oral fumaric acid esters for psoriasis over the last quarter century. Anecdotal reports of serious adverse reactions to DMF-MEF are also reviewed in this report.Expert opinion: DMF is generally safe and well tolerated. Flushing and gastrointestinal side effects are relatively common for the approved DMF dose but are ordinarily mild and self-limited. No increase in malignancies has been reported despite theoretical concerns. Although progressive multifocal encephalopathy has been reported anecdotally in 5 of > 196,000 patient-years of experience with fumaric acid esters, none of the 65,000 DMF MS patients treated in the first year has been affected.Appendix to the abstract: Subsequent to the acceptance of this article for publication, the manufacturer has notified physicians of the death of one patient from PML complicating use of DMF in the DEFINE study extension (ENDORSE). This does not alter the expert opinion rendered regarding the safety of DMF. We await the outcomes and recommendations from the ongoing investigation into this case.

KW - Dimethyl fumarate

KW - Fumarate

KW - Lymphopenia

KW - Monoethyl fumarate

KW - Multiple sclerosis

KW - Neuroprotection

KW - Nuclear factor (erythroid-derived-2)-like 2

KW - Progressive multifocal encephalopathy

UR - http://www.scopus.com/inward/record.url?scp=84918549243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918549243&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.977251

DO - 10.1517/14740338.2015.977251

M3 - Article

C2 - 25382392

AN - SCOPUS:84918549243

VL - 14

SP - 161

EP - 170

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 1

ER -